The Structural Genomics Consortium (SGC), an international public-private partnership that aims to determine three dimensional structures of medically important proteins, announced today the release into the public domain of its 1000th high resolution protein structure.
The 1000th structure known as JmjD2C belongs to a class of proteins involved in epigenetic signalling, a key research area for the SGC. Epigenetics is the study of inherited changes in gene expression caused by proteins such as JmjD2C which 'switch' genes on or off. It is believed that a better understanding of epigenetics could lead to new treatments for a wide variety of diseases including cancer, diabetes, obesity and many psychiatric diseases.
"JmjD2C is already known to play a key a role in the maintenance of self renewal in stem cells as well as roles in cancer," says Professor Udo Oppermann of SGC Oxford, who led the team solving the 1000th structure. "Now that its 3D structure is in the public domain, we hope that this will spur other scientists to investigate its functions more deeply and understand more clearly its role in epigenetics."
"This milestone reinforces the advantages of open-innovation partnerships between the public and private sectors," says Dr Aled Edwards the SGC Chief Executive. "We're extremely proud of this achievement and the efforts of our co-workers and their collaborators around the world."
Formed in 2004, the SGC comprises 180 scientists at labs at the Universities of Oxford and Toronto, and the Karolinska Institutet in Stockholm. The international collaboration is supported by public and private sector funding. All research output is made available to the research community free from restriction on use and protein structures are deposited in the Protein Data Bank (PDB). In 2009, the SGC contributed nearly a third of all new human proteins structures deposited in the PDB, and a similar fraction of protein structures fr
|Contact: Craig Brierley|